Perspective (CATX) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
0
Operating Income
-66.8M
Net Income
-79.3M
EPS (Diluted)
-$1.23
Balance Sheet Metrics
Total Assets
341.1M
Total Liabilities
50.4M
Shareholders Equity
290.7M
Debt to Equity
0.17
Cash Flow Metrics
Operating Cash Flow
-43.5M
Free Cash Flow
-72.7M
Revenue & Profitability Trend
Perspective Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 10.8M | 10.1M | 9.7M |
| Cost of Goods Sold | - | - | 6.2M | 4.9M | 4.6M |
| Gross Profit | - | - | 4.6M | 5.1M | 5.1M |
| Operating Expenses | 66.8M | 40.9M | 12.0M | 8.6M | 8.6M |
| Operating Income | -66.8M | -40.9M | -7.4M | -3.4M | -3.5M |
| Pre-tax Income | -80.4M | -40.1M | -7.3M | -3.4M | -3.4M |
| Income Tax | -2.1M | -2.7M | - | - | - |
| Net Income | -79.3M | -46.5M | -7.3M | -3.4M | -3.4M |
| EPS (Diluted) | -$1.23 | -$1.70 | -$0.50 | -$0.30 | -$0.50 |
Income Statement Trend
Perspective Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 231.2M | 16.8M | 59.3M | 67.3M | 5.5M |
| Non-Current Assets | 109.9M | 81.1M | 5.1M | 3.1M | 3.2M |
| Total Assets | 341.1M | 97.9M | 64.4M | 70.4M | 8.7M |
| Liabilities | |||||
| Current Liabilities | 18.2M | 15.7M | 2.3M | 1.8M | 1.6M |
| Non-Current Liabilities | 32.2M | 7.0M | 896.0K | 1.2M | 1.4M |
| Total Liabilities | 50.4M | 22.7M | 3.2M | 3.0M | 3.0M |
| Equity | |||||
| Total Shareholders Equity | 290.7M | 75.2M | 61.3M | 67.4M | 5.7M |
Balance Sheet Composition
Perspective Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -79.3M | -46.5M | -7.3M | -3.4M | -3.4M |
| Operating Cash Flow | -43.5M | -38.7M | -7.9M | -2.9M | -3.8M |
| Investing Activities | |||||
| Capital Expenditures | -54.1M | -1.1M | -266.0K | -380.0K | -273.0K |
| Investing Cash Flow | -218.9M | 24.4M | -284.0K | -410.0K | -287.0K |
| Financing Activities | |||||
| Dividends Paid | - | - | 0 | -9.0K | -11.0K |
| Financing Cash Flow | 275.9M | 231.0K | 0 | 64.2M | 863.0K |
| Free Cash Flow | -72.7M | -38.0M | -8.0M | -3.2M | -3.9M |
Cash Flow Trend
Perspective Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-3.34
Forward P/E
-3.20
Price to Book
0.90
Price to Sales
174.60
PEG Ratio
-3.20
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-6,383.63%
Return on Equity
-32.92%
Return on Assets
-15.56%
Financial Health
Current Ratio
17.02
Debt to Equity
1.34
Beta
1.12
Per Share Data
EPS (TTM)
-$1.23
Book Value per Share
$3.84
Revenue per Share
$0.02
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| catx | 256.8M | -3.34 | 0.90 | -32.92% | 0.00% | 1.34 |
| Abbott Laboratories | 231.9B | 17.31 | 4.75 | 30.65% | 31.89% | 27.09 |
| Boston Scientific | 149.9B | 73.94 | 6.75 | 9.50% | 11.58% | 52.16 |
| 908 Devices | 238.1M | -3.12 | 1.49 | -48.15% | -27.64% | 2.36 |
| MaxCyte | 230.7M | -5.68 | 1.16 | -19.63% | -110.92% | 9.44 |
| Tactile Systems | 236.4M | 15.41 | 1.17 | 8.12% | 5.52% | 21.23 |
Financial data is updated regularly. All figures are in the company's reporting currency.